Trial win boosts confidence in antibody treatment for coronavirus

22 June 2021

While GlaxoSmithKline (LSE: GSK) got off to a slow start in its bid to combat the novel coronavirus, the company looks set to make an increasingly meaningful contribution in the months to come.

With final positive Phase III data from the COMET-ICE trial, the British drugmaker and Californian firm Vir Biotechnology (Nasdaq: VIR) are ready to submit formally for approval for sotrovimab in the second part of 2021.

The firms already have an emergency approval in the USA for the investigational SARS-CoV-2 monoclonal antibody, and the European regulator has initiated a rolling review of the data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK